The transformative potential of antibody drug conjugates in NSCLC treatment is discussed, encompassing their design, bystander effect, biomarkers, and impact on the treatment landscape.
Dato-DXd Misses Significance for OS in Advanced Non-Small Cell Lung Cancer
May 29th 2024While Dato-DXd numerically improved overall survival for patients with non-small cell lung cancer, the data did not show statistical significance. However, a clinically meaningful benefit was observed in a subgroup of patients.
Read More
Differences in TKIs May Sway Choice of First-Line Therapy in ALK+ NSCLC
May 21st 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, asked participants their perspectives on the use of targeted agents for patients with ALK+ non–small cell lung cancer in the second article of a 2-part series.
Read More